The FGF19-fibroblast growth factor receptor (FGFR4)-bKlotho (KLB) pathway plays an important role in the regulation of bile acid (BA) homeostasis. Aberrant activation of this pathway has been described in the development and progression of a subset of liver cancers including hepatocellular carcinoma, establishing FGFR4 as an attractive therapeutic target for such solid tumors. FGF401 is a highly selective FGFR4 kinase inhibitor being developed for hepatocellular carcinoma, currently in phase I/II clinical studies. In preclinical studies in mice and dogs, oral administration of FGF401 led to induction of Cyp7a1, elevation of its peripheral marker 7alpha-hydroxy-4-cholesten-3-one, increased BA pool size, decreased serum cholesterol and diarrhea in dogs. FGF401 was also associated with increases of serum aminotransferases, primarily alanine aminotransferase (ALT), in the absence of any observable adverse histopathological findings in the liver, or in any other organs. We hypothesized that the increase in ALT could be secondary to increased BAs and conducted an investigative study in dogs with FGF401 and coadministration of the BA sequestrant cholestyramine (CHO). CHO prevented and reversed FGF401-related increases in ALT in dogs in parallel to its ability to reduce BAs in the circulation. Correlation analysis showed that FGF401-mediated increases in ALT strongly correlated with increases in taurolithocholic acid and taurodeoxycholic acid, the major secondary BAs in dog plasma, indicating a mechanistic link between ALT elevation and changes in BA pool hydrophobicity. Thus, CHO may offer the potential to mitigate elevations in serum aminotransferases in human subjects that are caused by targeted FGFR4 inhibition and elevated intracellular BA levels.
FGF401 is a highly selective and potent fibroblast growth factor receptor (FGFR4) inhibitor through binding to the kinase domain adenosine triphosphate-binding site of FGFR4 (Knoepfel et al., 2018) , a member of the FGFR family. FGF19, which signals through FGFR4 and its coreceptor bKlotho (KLB) (Lin et al., 2007) , plays a key role in the regulation of bile acid (BA) homoeostasis (Inagaki et al., 2005) and has also been associated with liver tumorigenesis (Lin and Desnoyers, 2012) , leading to a rising interest in inhibiting the FGF19-FGFR4 signaling axis in hepatocellular carcinoma (HCC) (Mellor, 2014; Wu et al., 2010) .
Intestinal BAs activate the nuclear transcription factor farnesoid X receptor (FXR) within enterocytes and induce the expression of FGF19. FGF19 is released into the portal vein and circulates to the liver where it binds to the FGFR4-KLB complex, leading to repression of Cyp7a1, the rate-limiting enzyme for BA synthesis (Inagaki et al., 2005) . Cyp7a1 converts cholesterol to 7-alpha-hydroxycholesterol, which is further oxidized to 7alpha-hydroxy-4-cholesten-3-one (C4), a stable BA intermediate and peripheral blood marker for hepatic Cyp7a1 activity (Galman et al., 2003) . The pathway subsequently drives the formation of the 2 primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) as illustrated in Figure 1 (Chiang, 2009) . Within hepatocytes, BAs are conjugated with glycine (G) or taurine (T) and transported into the bile canaliculi by BA transporters. In dogs, T-conjugation predominates, while in humans G-conjugated BAs are predominant (Schadt et al., 2016) . The bile fluid, which contains high millimolar concentrations of BAs, is subsequently stored in the gallbladder before it is released into the intestine upon food intake to facilitate lipid digestion. The filling of the gallbladder is regulated by FGF19, highlighting its importance in BA homeostasis (Jones, 2008) . Within the intestine, the primary BAs CA and CDCA are converted by the intestinal microflora to the secondary BAs deoxycholic acid (DCA) and lithocholic acid (LCA), respectively, and to a minor extent to ursodeoxycholic acid (UDCA). The secondary BAs DCA and LCA are generally more hydrophobic (due to the removal of a hydroxy group) and physiologically more potent as agonists of the BA receptors FXR or TGR5 (Duboc et al., 2014; Makishima et al., 1999; Parks et al., 1999) , but also more cytotoxic compared with CA (Sharma et al., 2010) due to the higher potential to disturb membrane integrity and mitochondrial function (Rolo et al., 2000) . The different aspects of BA toxicity in the context of liver homeostasis and drug-induced liver injury is reviewed elsewhere (Schadt et al., 2016) . The majority of intestinal BAs are reabsorbed by enterocytes, released into the portal vein, and taken up by the liver via the sinusoidal membrane. Only small amounts of BAs escape this enterohepatic cycling and are excreted via the feces, accounting for approximately 10%-20% loss per day (Dawson and Karpen, 2015; Thomas et al., 2008) .
The BA sequestrant cholestyramine (CHO) is a strong ion exchange resin that binds BAs in the intestine and forms insoluble complexes. Intestinal binding of BAs by CHO prevents BA reabsorption and leads to enhanced BA excretion by the feces. CHO is therefore used in the clinic for management of BA diarrhea (Westergaard, 2007) . In addition, it is also indicated to treat hypercholesterolemia due to its ability to lower serum cholesterol levels by increasing the conversion of hepatic cholesterol to BAs via indirect induction of hepatic Cyp7a1 (LaRosa, 1989) . Induction of hepatic Cyp7a1 occurs secondary to CHO-mediated intestinal depletion of BAs, which prevents BA-mediated activation of the endocrine FXR-FGF19-FGFR4-KLB pathway (Thomas et al., 2008) .
FGFR4 knockout mice have a larger BA pool with increased excretion of BAs, enhanced expression of Cyp7a1, BA-depleted gall bladders (Xie et al., 1999; Yu et al., 2000) , and hypercholesterolemia (Huang et al., 2007) . Similar findings are reported for FGF15 knockout mice (mouse FGF19 ortholog) (Choi et al., 2006) and KLB knockout mice (Ito et al., 2005) . Liver toxicity characterized by single cell necrosis and increased bilirubin, severe diarrhea, and decreased food consumption have previously been reported in cynomolgus monkeys given single or repeated doses of an anti FGF19 monoclonal antibody, and were presumably secondary to increased BAs (Pai et al., 2012) .
Single or repeated doses of FGF401 to dogs led to induction of Cyp7a1 in the liver resulting in increased plasma and fecal BA content, was associated with decreased serum cholesterol and diarrhea, and increased serum alanine aminotransferase (ALT) in the absence of adverse histopathological findings in the liver, or in other organs that could be a source of ALT. In order to assess if ALT perturbation could have been secondary to BA increases and its potential mitigation, we conducted an investigative study in dogs cotreated with FGF401 and the BA sequestrant CHO to address this hypothesis. CHO may offer the potential to mitigate elevations in serum aminotransferases that are caused by targeted FGFR4 inhibition and increased BA pool size, in addition to its established role in diarrhea management.
MATERIALS AND METHODS
Animals and treatment. For the 4-week toxicity study, male and female beagle dogs obtained from Marshall BKU Ltd (Grimston, UK) were approximately 1012 months of age, and weighed 5.7-10.2 kg at the initiation of dosing. In this study, FGF401 was administrated as a solution in 100 mM citrate buffer, pH 2.5, by oral gavage to groups of 3 or 5 dogs per sex at dosages of 0 (vehicle), 5, 15, and 45 mg/kg/d using a dosage volume of 5 mL/kg. After cessation of treatment, 2 animals per sex in the control and high-dose group were maintained on the study for a 4-week recovery period. For the nonterminal investigative study, male beagle dogs obtained from Marshall BioResources (North Rose, New York), were approximately 7 months to 3 years of age, and weighed 7.2-11.1 kg at the initiation of dosing. FGF401 (Novartis Pharma AG, Basel, Switzerland) and CHO (Questran Powder [CHO for Oral Suspension, USP]; NDC no. 49884-09366-66; lot no. 26079601; PAR Pharmaceutical Companies, Inc., Spring Valley, New York) were each administered by oral gavage to beagle dogs as a formulation in their respective vehicles [FGF401, in 100 mM citrate buffer, pH 2.5; CHO, in drinking water]. The dose volume for the FGF401 formulation was 5 ml/kg. For CHO, the dosing aliquot was administered in 75 ml drinking water. For the investigative dog study, an initial feasibility study phase was conducted to investigate potential effects of CHO on the tolerability and exposure profile of FGF401. For this purpose, 6 stock animals were administered FGF401 at a single dose of 5 mg/kg, followed by dosing with vehicle to CHO (first 3 animals) or CHO at 5 g/dog, corresponding to 11.25 g Questran powder (last 3 animals), approximately 2 h later. Food was presented after the second dosing event. Blood was collected for determination of FGF401 plasma concentrations at approximately 0.5, 1, 3, 7, and 24 h after FGF401 administration. Animals were returned to colony on day 2. For the main study phase of the investigative study, a crossover design was applied. Two groups of 6 naïve animals were used (group 1 with animal nos. 1001-1006 and group 2 with animal nos. [2001] [2002] [2003] [2004] [2005] [2006] . The main study phase started with dosing of either vehicle or CHO at 5 g/animal for 1 week (phase I). FGF401 dosing at 5 mg/kg/d was initiated on study day 8 (phase II), followed approximately 2 h later by a second administration of either vehicle or CHO (5 g/animal) at each day. Food was presented to the animals after the second daily dosing event. Animals were not dosed on study days 15-24 (washout/recovery period, phase III). Dosing with FGF401/CHO was restarted on study day 25 (phase IV) and the dose groups crossed over on study days 39-44 (phase V), with the last day of dosing on study day 44. The animals were returned to colony on study day 53. The administration schedule including cross-over design is shown in Figure 5 .
Study approval and animal welfare. These studies were performed in accordance to the respective national animal welfare regulations and approved animal study licenses. The 4-week toxicity dog study was conducted in accordance with the requirements of the UK law (Animals [Scientific Procedures] Act 1986). The nonterminal investigative dog study was conducted in accordance with the United States Department of Agriculture Animal Welfare Regulations and with the Novartis Animal Care and Use Committee-approved protocol no. TX 4039.
Clinical pathology. In the 4-week dog toxicity study, blood samples for clinical chemistry (eg, serum ALT, aspartate aminotransferase [AST], total cholesterol) were collected once before initiation of dosing (pretest), on treatment days 2, 8, 15, 22, and 26 approximately 24 h postdose, and on days 3, 8, 15, and 26 of the treatment-free recovery period. In the investigative dog study, blood samples for clinical pathology assessments were collected once during pretest (hematology, clinical chemistry, and coagulation) for both the feasibility study phase and the main study phase. For the main study phase, blood sampling In contrast, inhibition of FGFR4 by FGF401 leads to transcriptional activation of Cyp7a1 in the liver and thus to BA biosynthesis. Hepatic Cyp7a1 activity can indirectly be monitored in a noninvasive way by the blood marker C4, which is an intermediate in BA biosynthesis and used as surrogate PD readout for FGFR4 inhibition in the present dog studies.
for clinical chemistry was conducted at approximately 3 h postdose (postvehicle, CHO, or FGF401 dosing, as appropriate, or at similar time of the day during washout periods) on study days 1, 3, 7, 8, 11, 14, 15, 18, 21, 23, 25, 28, 31, 35, 38, 42, and 45. Toxicokinetics. Plasma samples for toxicokinetic (TK) analysis were collected from all animals approximately 0.5, 1, 3, 7, and 24 h postFGF401 dosing on study days 1 and 26 of the 4-week toxicity study, as well as in the single-dose feasibility phase and in the main study phase on study days 8, 14, 25, 39, and 44 of the investigative study. C4/BA profiling by liquid chromatography-mass spectrometer. Plasma samples for BA profiling and C4 analysis were collected on study days 1 and 26 concurrent to TK sample collection in the 4-week toxicity study, and in the investigative study during the main study phase concurrent with clinical chemistry and TK. Feces samples for BA analysis were collected at the end of treatment week 4 in the 4-week study, and in the investigative study at pretest and on study days 7 and 49 of the main study phase. BA profiles and C4 analyses were carried out on an Agilent (Waldbronn, Germany) 1290 Infinity ultra high-performance liquid chromatography (UPLC) system interfaced to an ABSciex (Darmstadt, Germany) API4000 triple.quadrupole tandem mass spectrometer (LC-MS/MS) operated in positive electrospray ionization mode. Chromatographic separation was conducted on a Waters Acquity UPLC (Milford, Massachusettes) BEH C18, 1.7 mm, 2.1 Â 150 mm column heated to 70 C at a flow rate of 0.45 ml/min. Mobile phase A was 95% water þ 5% acetonitrile (ACN) þ 0.1% formic acid (FA), and mobile phase B was 95% ACN þ 5% water þ 0.1% FA. Separation was achieved by a linear gradient from 30% B to 40% B at 0-8 min, increasedto 70% B from 8 to 18 min, followed by isocratic washout at 100% B from 18.2 to 21 min. The monitored transitions of each BA are listed in Table 1 . All data were acquired and analyzed using Analyst 6.1 data processing software (ABSciex, Darmstadt, Germany). Reference standards and deuterated internal standards (IS) for calibration and quantification were obtained from Sigma-Aldrich (Buchs, Switzerland) (CA, CDCA, DCA, LCA, taurochenodeoxycholic acid
and Toronto Research Chemicals (Toronto, Ontario, Canada) (C4 and d7-C4). All other chemicals and reagents were purchase from Sigma-Aldrich (Buchs, Switzerland) and were of the highest purity available. Stock solutions for BA and IS were prepared in methanol (MeOH, 10 mM), combined and diluted to obtain mixed working solutions for BAs and IS at concentrations of 100 mM, each. Calibration standards for analysis of plasma samples were prepared by spiking defined volumes of serially diluted BA working solutions to 50 ml of aqueous 20% bovine serum albumin solution (fatty acid free). Quality control (QC) samples were prepared in control mouse, rat, and dog plasma containing a low, mid and high concentration of each analyte. Plasma samples (50 ml), QCs and calibration standards were processed by addition of 50 ml of mixed IS working solution and 450 ml ACN and thoroughly mixed. Samples were centrifuged at >14 000 Â g for 15 min at 4 C, the supernatants were transferred into new tubes and evaporated to dryness in a vacuum centrifuge. After reconstitution in 60 ml MeOH/water 1: 1 (v/v) containing 0.1% FA, 5 ml were injected into the LC-MS/MS system for analysis. For BA analysis in feces, a multi-step extraction procedure was applied using solvents with different polarities and acidification according to a protocol by Manes et al. (1971) with modifications, to enable BA extraction both from naïve and CHO containing feces. An aliquot of approximately 2 g of fecal sample was accurately weighed in a glass flask, diluted 1:10 (w/w) in water, mixed and allowed to soak/swell at 4 C. The samples were thoroughly mixed to obtain a homogenous slurry. In total 2 ml of the homogenous slurry (corresponds to 200 mg fecal samples) were transferred into a weighed 15-ml plastic tube and centrifuged at 5000 Â g for 10 min. The supernatant was removed, transferred into a new tube, and later combined with the extracts of the 4 subsequent extraction steps of the residual pellet, which were as follows: 4 ml of MeOH, 4 ml of ACN and 2 Â 4 ml of acidified ethanol containing 0.5 N hydrochloric acid. An aliquot (900 ll) of the combined extracts was transferred into a new tube, spiked with IS, mixed, and evaporated to dryness in a vacuum centrifuge. After reconstitution in 500 ml MeOH/water 1:1 (v/v) containing 0.1% FA, 5 ml were injected into the LC-MS/MS system for analysis. Calibration standards were prepared by spiking defined volumes of serially diluted BA working solutions to a mixture of MeOH:ACN: water 4:4:1 to reflect a similar solvent constitution as in the samples, evaporated to dryness in a vacuum centrifuge and reconstituted in 500 ll MeOH/water 1:1 (v/ v) containing 0.1% FA for LC-MS/MS analysis. The dry weight of the fecal samples was determined by drying the residual pellet after extraction to constant weight.
microRNA analysis (miR-122). Plasma samples for microRNA analysis were collected from all animals during the main study phase of the investigative study time-matched with clinical chemistry sample collection. MicroRNA analysis was performed according to a protocol published by Thompson et al. (2016) . Small RNA was extracted from 50 ml of plasma by using the miRNeasy/MinElute kit and following the instructions of the Analysis of mRNA expression in liver. Liver samples for mRNA levels analysis were collected at scheduled necropsy at approximately 4 h postlast FGF401 dose administration in the 4-week toxicity study and immediately snap frozen in liquid nitrogen. Total RNA was extracted by acid guanidinium thiocyanatephenol-chloroform extraction (Trizol, Invitrogen Life Technologies) from each frozen tissue section and the total RNA was purified on an affinity resin (Rneasy, Qiagen, Hilden, Germany) according to the manufacturer's protocol. Total RNA was quantified by the absorbance at k ¼ 260 nm (A260nm), and the purity was estimated by the ratio A260nm/A280nm. RNA integrity was controlled by running a Bioanalyzer profile (Agilent, Waldbronn, Germany). RNA was stored at À80 C until analysis. 300 ng of total RNA was reverse transcribed into cDNA by using the High Capacity cDNA Archive Kit according to the manufacturer protocol (Applied Biosystems/Life Technologies, Zug, Switzerland). PCR was performed in triplicate from 6 ng of cDNA by using the SYBR Green Real-time PCR master mix following the instructions of the manufacturer (Applied Biosystems Statistics. GraphPad Prism 7.03 (GraphPad Software, La Jolla, California) was used for statistical analysis and plotting of data. Data are expressed as mean 6 SEM. Differences among multiple groups were examined using 1-way ANOVA with Dunnett's multiple comparison test versus control group. Differences between 2 groups were evaluated using an unpaired, 2-tailed Student's t test. p values below .05 were considered significant. TIBCO Spotfire (Palo Alto, California) was used for correlation analysis by linear regression.
RESULTS

FGF401
Induced BA Biosynthesis, Increased Serum ALT and Decreased Cholesterol in the 4-Week Dog Toxicity Study Repeated oral (gavage) administration of FGF401 to beagle dogs for 4 weeks at dose levels of 5, 15, and 45 mg/kg/d was overall well tolerated with only limited, dose-dependent in-life signs such as salivation, vomiting, and liquid or soft feces. In the liver, the treatment with FGF401 resulted in a significant increase in Cyp7a1 mRNA levels (Figure 2A ) which confirms blockage of the FGFR4 receptor by FGF401. The lack of a clear dose-response relationship after 4 weeks of treatment suggests full target saturation and signaling pathway activation already at the 5 mg/kg/d dose with no further enhancement at higher doses or exposures. Consistent with the upregulation of Cyp7a1, the transcript of NR0B2 coding for the small heterodimer partner (SHP) was downregulated (Figure 2A ). SHP is a nuclear factor without DNA binding domain and a repressor of transcription factors, such as HNF4alpha and LRH-1, which are involved in the transcriptional activation of Cyp7a1 (Kir et al., 2012) . It is required for repression of Cyp7a1 by FGF15/19 (Inagaki et al., 2005) , thus its downregulation is a direct effect of FGFR4 inhibition, resulting in upregulation of Cyp7a1. Transcription of Cyp8b1 and Cyp27a1 was not modulated by FGF401 (data not shown). Treatment with FGF401 at doses > 5 mg/kg/day led to increased levels of C4 in plasma starting between 3 and 7 h postdose on day 1 (Figure 2C ), being sustained and more pronounced after 4 weeks of treatment ( Figure 2D ). These changes in C4 were consistent with induction of hepatic Cyp7a1 both after single (data not shown) and repeated dose administration (Figure 2A ). The hepatic influx transporter Oatp1a1 (Slco1a1), involved in uptake of BAs from the blood into the liver, was downregulated by FGF401 ( Figure 2E ), whereas the Ost-b subunit (Slc51b) of the basolateral organic solute transporter Ost-a/Ost-b was upregulated ( Figure 2F ). No clear treatment-related transcriptional modulations were observed for the BA transporters Ntcp (Slc10a1), Bsep (Abcb11), Mrp2 (Abcc2), Bcrp (Abcg2), and Mrp3/4 (Abcc3/Abcc4) in the dog (data not shown).
Analysis of the BA profiles showed that the major BA components in control dog plasma were taurine-conjugated TCA (39%), TCDCA (25%), TDCA (21%), TLCA (4%), and unconjugated CA (7%) ( Figure 3A) , whereas in control dog feces, the unconjugated secondary BAs DCA (61%) and LCA (28%) were most abundant with lower amounts of the unconjugated primary BAs CA (5%) and CDCA (3%) ( Figure 3B ). Treatment at doses !5 mg/kg/d FGF401 for 4 weeks resulted in increases in the major BA components in plasma ( Figure 3C ), which was already evident after a single administration at doses ! 15 mg/kg/d, yet less pronounced (data not shown). Consistent with the FGF401-related increases in plasma BAs, the corresponding unconjugated primary and secondary BAs were also increased in fecal samples upon treatment ( Figure 3D ). Taken together, the data indicated a general increase in BA pool size upon FGF401 treatment as a consequence of increased BA biosynthesis due to FGFR4 inhibition.
Dogs treated with FGF401 showed mildly decreased total cholesterol concentrations in serum ( Figure 4A , both high-and low-density lipoprotein cholesterol) and minimally to moderately (1.5-to 5.6-fold) increased serum ALT at all doses ( Figure 4B ). Effects on ALT and cholesterol concentrations were more apparent from treatment day 8, did not become progressively more severe over time and exhibited reversibility at the end of the 4-week treatment-free phase. Minimal increases in serum AST ( 1.7-fold, Figure 4C ) in individual animals were also noted, particularly in those with the highest levels of ALT. Despite the increase in ALT, there were no adverse histopathological findings in the liver or in any other organs. The occurrence of liquid/soft feces and the decrease in serum cholesterol were likely the consequence of increases in BA biosynthesis, pool size and intestinal BA content (Hofmann, 2009; Thomas et al., 2008) . However, the cause for the transient increase in ALT without histopathological correlate remained undetermined in the 4-week toxicity study.
Investigative Dog Study With FGF401 Treatment and Coadministration of CHO
The investigative dog study was designed to address whether the FGF401-mediated ALT increase was secondary to increases in BAs and could be prevented and reversed by coadministration of the BA sequestrant CHO. A crossover study design with different phases and washout periods was applied in order to increase the statistical power and identify non-, weak-, or strong responders, and follow-up on the timecourse of FGF401-induced effects with and without CHO intervention ( Figure 5 ). FGF401 was administrated at a dose of 5 mg/kg/d, and CHO at a dose of 5 grams per animal approximately 2 h after FGF401 administration, both by oral gavage. In an initial feasibility study phase the effects of CHO administration on tolerability and FGF401 exposure profile were investigated. CHO was well tolerated and did not compromise the absorption or change the exposure profile of FGF401 (data not shown).
CHO Mitigates and Reverses FGF401 Mediated Increases in ALT
As shown in Figure 6 , the treatment with FGF401 alone caused minimal to moderate increases in serum ALT ( 4.3-fold), whereas coadministration of FGF401 with CHO did not result in increased ALT levels. Furthermore, ALT decreased relatively quickly to pretest values when FGF401 administration was discontinued or by giving CHO to dogs being treated with FGF401. In contrast, stopping administration of CHO and continuing FGF401 administration resulted in an increase in ALT.
CHO Prevents FGF401 Mediated Increases in Plasma BAs by Increased Fecal Excretion
As expected, the treatment with the BA sequestrant CHO led to increased fecal excretion of BAs as confirmed by the increased BA content in feces (Figs. 7A and 7B) , and decreased the BA concentrations in plasma ( Figure 7C ). This effect was most pronounced for the hydrophobic secondary BAs DCA and LCA in feces ( Figure 7B ) and their corresponding taurine-conjugates TDCA and TLCA in plasma ( Figure 7C ). Consistent with our observation in the 4-week dog study, treatment with FGF401 alone resulted in increases in plasma BAs ( Figure 8A ), driven both by primary ( Figure 8B ) and secondary BAs ( Figure 8C ). When FGF401 was coadministered with CHO, plasma BA concentrations remained comparable to untreated controls or were even decreased ( Figure 8A ), this effect being more pronounced for the secondary BAs TDCA and TLCA ( Figure 8C ). When FGF401 administration was discontinued or when CHO was coadministered to dogs being treated with FGF401, increased plasma BA levels decreased relatively quickly to or below untreated control values. Thus, the FGF401-mediated increases in plasma BAs could be mitigated and reversed by cotreatment with CHO, overall in a similar way as CHO was able to mitigate and reverse FGF401-mediated increases in serum ALT.
Potential Association Between Hydrophobic BAs and ALT Increase
Correlation analysis at peak ALT levels revealed that the FGF401-mediated increase in serum ALT correlated best with plasma BAs of high hydrophobicity, such as TLCA (study day 14: r 2 ¼ 0.79, p < .001; study day 38: r 2 ¼ 0.83, p < .0001), TDCA (study day 14: r 2 ¼ 0.82, p < .0001), the sum of these secondary BAs (study day 14: r 2 ¼ 0.82, p < .0001; study day 38: r 2 ¼ 0.57, p < .01), and the ratio of hydrophobic to polar BAs (sum of TLCA, TDCA, TCDCA divided by sum of TCA, CA; study day 14: r 2 ¼ 0.72, p < .001; study day 38: r 2 ¼ 0.73, p < .001). These data therefore suggest a prominent role of hydrophobic, particularly secondary BAs in the mechanism of ALT elevation, and thus of the hydrophobicity of the BA pool. These secondary BAs are formed in the intestine by the microbiome at high abundance, and were also the ones most affected by the treatment with CHO.
Effect of FGF401 and CHO on Cholesterol and C4
As shown in Figure 9A , treatment with FGF401 or CHO resulted in decreased serum total cholesterol concentrations, which quickly reversed to pretest levels upon treatment discontinuation. Consistent with our data from the 4-week toxicity study, treatment of dogs with FGF401 increased plasma C4 concentrations, which became apparent after the first administration and appeared to plateau after 6-7 days of repeated daily dosing ( Figure 9B ). As expected, when CHO was administrated alone in the first phase of the study, plasma C4 concentrations increased as well, indicating induction of hepatic Cyp7a1 activity by the CHO treatment. When FGF401 was coadministered with CHO, plasma C4 concentrations further increased compared with FGF401 or CHO administration alone, which resulted in an additive elevation of C4 levels.
Analysis of miR-122 in Plasma as Marker for Hepatocellular Injury
Exploratory miR-122 analysis was conducted in plasma as a biomarker for hepatic injury to investigate whether the liver might be the source of FGF401-mediated ALT elevation despite the lack of observable histopathological changes. Overall, circulating miR-122 levels were highly variable over the course of the study. The treatment with FGF401 did not result in a consistent change in plasma miR-122 with the exception of 2 individual animals, which showed minimal to moderate increases in miR-122 when treated with FGF401 alone (Figure 10 , study days 25-38), followed by a trend towards a decrease after cotreatment with CHO. The highest level of miR-122 and ALT was seen in 1 out of these 2 animals, suggesting a hepatocellular origin of the ALT increase in that dog. Otherwise, there was no clear correlation between FGF401-induced ALT elevation and changes in miR-122, although miR-122 appeared slightly more elevated in FGF401 treated animals than with FGF401-CHO combination.
DISCUSSION
Inhibition of the FGF19-FGFR4-KLB pathway is a promising approach to treat patients with HCC, but is generally associated Figure 5 . Investigative dog study with FGF401 and CHO. Crossover study design of the investigative dog study with 5 mg/kg/d FGF401 administration and coadministration of the BA sequestrant CHO (5 g per animal) . In phase I, the effect of CHO on BAs and clinical chemistry parameters was assessed. In study phases II and V, group 1 animals were daily treated with FGF401 (vehicle to CHO was water), while group 2 animals were daily treated with FGF401 and CHO (approximately 2 h postFGF401 administration). Phase IV consisted of a treatment crossover, phases III and VI were washout/recovery phases without any treatment (n ¼ 6 per group). Figure 6 . Changes in ALT in investigative dog study with FGF401 and CHO. Treatment with CHO did not affect serum ALT levels (phase I study days 1-7). Treatment with 5 mg/kg/d FGF401 alone resulted in minimal to moderate increases in serum ALT (group 1: phase II study days 8-14 and phase V study days 39-44; group 2: phase IV study days 25-38), which could be mitigated and reversed by coadministration with the BA sequestrant CHO (group 2: phase II study days 8-14 and phase V study days 39-44; group 1: phase IV study days 25-38). Discontinuation of FGF401 treatment (recovery/washout phase III study days 15-24 and phase VI study day 45 onwards) or administering CHO on FGF401 (group 2: crossover from phases IV to V) rapidly decreased ALT levels to pretest control values (n ¼ 6 per group). Mean 6 SEM are shown.
with modulation of BA homeostasis and increased BA pool size (Mellor, 2014) . Indeed, we showed that blockage of the FGFR4 receptor by the antagonist FGF401 led to downregulation of the transcriptional repressor SHP and upregulation of Cyp7a1 mRNA in the liver, increased BA biosynthesis and BA content in plasma and feces in mice and dogs. The treatment with FGF401 was also associated with transient, minimal to mild increases in serum ALT without adverse histopathological findings in the liver or in any other tissues, making the cause of the ALT elevation unclear. We therefore sought to determine whether the FGF401-mediated increase in ALT was secondary to increased BAs and conducted an investigative study in dogs with FGF401 treatment and coadministration of the BA sequestrant CHO. Administration of CHO alone did not affect levels of ALT in dogs which was tested in the initial phase of the investigative study in view of some clinical reports in healthy volunteers associating CHO treatment with increases in ALT (Singhal et al., 2014) . No treatment-related effects on mortality/moribundity, clinical signs, body weight, or food consumption parameters were observed at any dose or combination of doses with FGF401 and CHO. The lower levels of serum total cholesterol with FGF401 were also noted in the 4-week dog study with daily dosing of FGF401. In addition, decreases in serum total cholesterol became apparent in dogs treated with CHO alone, which was an anticipated effect of intestinal sequestration of BAs (LaRosa, 1989) . In both cases, the mechanism behind the reduction in serum cholesterol is likely increased BA synthesis in the liver, which leads to increased consumption and subsequent depletion of hepatic cholesterol and in turn to increased cholesterol uptake from the circulation (Thomas et al., 2008) . Consistently, plasma C4 levels measured to monitor hepatic Cyp7a1 activity (Galman et al., 2003) were increased in dogs treated with FGF401 or CHO alone, or with combinations thereof. Thus, circulating C4 appears to be a suitable surrogate marker for the pharmacodynamic response of FGFR4 antagonism in vivo, but needs to be interpreted with caution in situations where an FGFR4 inhibitor is coadministered with CHO in patients. FGF401-mediated increases in serum ALT were directly modulated by coadministration of CHO. Indeed, coadministration of FGF401 and CHO prevented an increase in ALT, whereas administration of FGF401 alone caused increased ALT levels up to approximately 4-fold in single animals compared with baseline. Following the same time-course, FGF401 administration alone increased plasma BA concentrations due to increased biosynthesis paralleling the elevation in ALT, which was prevented and reversed by coadministration with CHO. CHO binds BAs within the intestine, prevents their absorption and leads to increased fecal excretion as shown by the increased BA content in feces, which in turn decreased BAs in the circulation and reversed FGF401-related increases. Our results therefore demonstrate that lowering the amount of free BAs in the intestine by CHO can prevent both FGF401-mediated increases in circulating BAs and ALT. In the ongoing clinical trial with FGF401 in HCC patients, we have also observed a trend towards lower levels of serum aminotransferases in subjects cotreated with CHO for management of diarrhea. These clinical data, while early and limited, suggest that CHO may have the potential to mitigate transaminase increases in these patients, consistent with our results of the investigative dog study.
By investigating the potential association between individual BA components and changes in ALT throughout the course of the investigative study, it appeared that the secondary BAs TLCA and TDCA were strongly associated with increases in ALT. These secondary BAs, formed in the intestine by the microbiome (Hofmann, 1999) and generally more hydrophobic compared with primary BAs, were strongly reduced in the circulation by the treatment with CHO, are physiologically more potent as agonists of the BA receptors FXR or TGR5 (Duboc et al., 2014; Makishima et al., 1999; Parks et al., 1999) , and exhibit higher cytotoxicity compared with the more polar ones (Roda et al., 1990) due to a higher potential to disturb membrane integrity and mitochondrial function (Rolo et al., 2000) . Thus, a mechanistic link between the FGF401-mediated elevation in ALT and increased BAs, particularly of those with high hydrophobicity, appears plausible and could involve various mechanisms including direct BA-induced hepatocyte toxicity. However, a direct hepatotoxic effect of BAs on the liver as a potential cause for FGF401-mediated ALT elevation was not supported by our data , TCDCA) . C, Secondary BAs in plasma (TLCA, TDCA), for which CHO-mediated reductions appeared to be slightly more pronounced (n ¼ 6 per group). Mean 6 SEM are shown. *p < .05, ** p < .01, and *** p < .001, by students t test groups 1 versus 2.
based on the absence of histopathological findings in the 4-week dog toxicity study. To gain more insights into the mechanism of ALT elevation we looked into the expression levels of Gpt, the gene coding for ALT in the liver. We hypothesized, that, even without signs of liver injury, a potential treatment-related upregulation of Gpt could be sufficient to increase circulating basal levels of ALT due to the normal turnover of hepatocytes and related leakage of intracellular content. However, Gpt expression was not increased by the treatment (data not shown).
To further investigate the origin of ALT elevation in the nonterminal investigative dog study, analysis of circulating miR-122 as an exploratory biomarker for hepatic injury was conducted (Starkey Lewis et al., 2012) . Although miR-122 appeared slightly higher in FGF401-treated animals than with the FGF401-CHO combination in some phases of the study, there was no consistent change and the results overall did not clearly correlate with the observed increases in ALT. For 1 animal there appeared to be a clear correlation between increases in plasma miR-122 and ALT upon FGF401-treatment, which points towards a hepatic origin of the ALT in that specific dog. Interestingly, the same animal had among the highest levels of plasma TLCA upon FGF401 treatment, which is a highly hepatotoxic BA in experimental animals (Hofmann, 1999) and might have affected the membrane integrity and caused leakage from hepatocytes. In humans, TLCA is efficiently sulfated at position C-3 which prevents its reabsorption from the intestine and leads to excretion in feces (Hofmann, 1999) .
A number of publications show increased serum liver enzyme levels in the absence of liver injury, and various potential mechanism have been investigated (Ennulat et al., 2010; Gaskill et al., 2005) .
Increased serum enzyme levels without signs of hepatic injury can be due to reduced Kupffer cell-mediated clearance of serum enzymes (Radi et al., 2011; Wang et al., 2011) . Kupffer cells are resident macrophages lining the hepatic sinusoids that clear several serum enzymes by phagocytosis and endocytosis, including creatinine kinase and aminotransferases. It was shown that reducing the number of Kupffer cells, eg, by neutralizing and FGF401 to dogs resulted in additional effects on plasma C4 elevation (n ¼ 6 per group). Mean 6 SEM are shown. *p < .05, ** p < .01, and *** p < .001, by students t test groups 1 versus 2. macrophage colony-stimulating factor via an antibody, led to increased serum enzymes levels without evidence of tissue injury (Radi et al., 2011) . Interestingly, Kupffer cells express the BA receptor TGR5 and are functionally suppressed in the presence of hydrophobic BAs, which transiently attenuate their phagocytic activity (Keitel et al., 2008; Sung and Go, 1999) . The potency of BAs on the TGR5 receptor is ranked in the order LCA ! DCA > CDCA > CA, with a stronger activation potential for the corresponding T-conjugated BAs TLCA ! TDCA > TCDCA > TCA (Duboc et al., 2014) . Notably, the results of our investigative dog study with FGF401 and coadministration of CHO indicates an association between FGF401-mediated increases in serum ALT and increases in BAs, predominantly with the secondary BAs of high hydrophobicity such as TLCA and TDCA. Thus, it could be speculated that the transient increase in serum ALT without signs of liver injury might have been caused by a transient reduction of phagocytic Kupffer cell activity due to increased activation of the TGR5 receptor by TLCA and TDCA, leading to decreased clearance. Such a mechanism would be consistent with the observed association between increases in circulating ALT and the secondary BAs TLCA and TDCA in dogs after treatment with FGF401 and the possibility to mitigate this effect by CHO. In addition to Kupffer cells, liver sinusoidal endothelial cells (LSEC) are also involved in the clearance of serum enzymes and immunoglobulins by endocytosis Iwamura et al., 1995; Kamimoto et al., 1985) and are responsive towards specific BAs by expressing the TGR5 receptor (Keitel et al., 2007) . Whether TGR5 and thus BAs are directly involved in the regulation of the endocytic activity of LSECs has not been investigated by our group. For LSECs, differences in the clearance kinetic and specificities for serum enzymes have been reported Kamimoto et al., 1985 . This could explain why different serum aminotransferases are differently affected by changes in BAs concentrations. Considering their localization within the sinusoid, both LSECs and Kupffer cells are exposed to high concentrations of secondary, hydrophobic BAs from the portal blood after intestinal reabsorption, and thus with high local abundance of their primary TGR5 ligands at their cell surface. However, further investigations are necessary to characterize such a mechanism, which in principle could cooccur with minimally increased hepatocyte leakage induced by hydrophobic BAs, yet without visible alterations at histopathological examination.
In conclusion our data showed that coadministration of the BA sequestrant CHO prevented and reversed FGF401-mediated increases in serum ALT. Results suggest that CHO may have utility to mitigate FGFR4-inhibition, BA-induced serum transaminase elevations in the clinic.
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